Cooper Companies (NASDAQ:COO) Cut to Neutral at Rothschild & Co Redburn

Rothschild & Co Redburn downgraded shares of Cooper Companies (NASDAQ:COO) from a buy rating to a neutral rating in a report released on Wednesday, Marketbeat reports. The firm currently has $85.00 target price on the medical device company’s stock.

Other equities analysts have also issued reports about the company. The Goldman Sachs Group restated a “sell” rating and set a $73.00 target price on shares of Cooper Companies in a report on Friday, January 9th. Barclays set a $98.00 price target on Cooper Companies and gave the stock an “overweight” rating in a research note on Monday, January 26th. Piper Sandler reissued an “overweight” rating and set a $94.00 price objective (up from $83.00) on shares of Cooper Companies in a report on Friday, December 5th. Morgan Stanley raised their price objective on Cooper Companies from $76.00 to $83.00 and gave the company an “equal weight” rating in a research note on Monday, December 8th. Finally, Wells Fargo & Company boosted their target price on Cooper Companies from $72.00 to $82.00 and gave the stock an “equal weight” rating in a report on Friday, December 5th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $90.79.

Cooper Companies Stock Performance

COO stock opened at $76.55 on Wednesday. The firm has a 50 day moving average of $82.11 and a two-hundred day moving average of $75.97. Cooper Companies has a 12 month low of $61.78 and a 12 month high of $89.83. The company has a market capitalization of $14.94 billion, a price-to-earnings ratio of 37.90, a P/E/G ratio of 2.29 and a beta of 1.02. The company has a quick ratio of 1.13, a current ratio of 1.89 and a debt-to-equity ratio of 0.30.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings results on Thursday, March 5th. The medical device company reported $1.10 earnings per share for the quarter, beating analysts’ consensus estimates of $1.03 by $0.07. Cooper Companies had a net margin of 9.67% and a return on equity of 10.36%. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter last year, the firm earned $0.92 EPS. Cooper Companies’s revenue for the quarter was up 6.2% on a year-over-year basis. Cooper Companies has set its Q2 2026 guidance at 4.580-4.660 EPS. As a group, equities analysts anticipate that Cooper Companies will post 3.98 EPS for the current fiscal year.

Insider Activity

In other Cooper Companies news, Director Lawrence Erik Kurzius acquired 2,000 shares of the company’s stock in a transaction dated Wednesday, December 17th. The shares were acquired at an average cost of $82.50 per share, for a total transaction of $165,000.00. Following the completion of the purchase, the director owned 7,777 shares of the company’s stock, valued at approximately $641,602.50. This trade represents a 34.62% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Maria Rivas acquired 1,000 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The shares were acquired at an average cost of $82.13 per share, with a total value of $82,130.00. Following the transaction, the director directly owned 11,141 shares in the company, valued at $915,010.33. The trade was a 9.86% increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have acquired 16,014 shares of company stock worth $1,304,416. Insiders own 2.08% of the company’s stock.

Institutional Trading of Cooper Companies

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its position in shares of Cooper Companies by 1.8% in the second quarter. Vanguard Group Inc. now owns 24,254,677 shares of the medical device company’s stock valued at $1,725,963,000 after acquiring an additional 421,423 shares during the period. Capital World Investors increased its position in Cooper Companies by 25.7% during the third quarter. Capital World Investors now owns 10,551,592 shares of the medical device company’s stock worth $723,417,000 after acquiring an additional 2,159,233 shares during the period. State Street Corp raised its stake in Cooper Companies by 2.4% during the 4th quarter. State Street Corp now owns 8,793,747 shares of the medical device company’s stock valued at $720,736,000 after purchasing an additional 207,195 shares during the last quarter. Wellington Management Group LLP raised its stake in Cooper Companies by 332.9% during the 3rd quarter. Wellington Management Group LLP now owns 6,184,992 shares of the medical device company’s stock valued at $424,043,000 after purchasing an additional 4,756,178 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in Cooper Companies by 58.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,028,821 shares of the medical device company’s stock valued at $494,123,000 after purchasing an additional 2,231,568 shares during the period. Institutional investors and hedge funds own 24.39% of the company’s stock.

Key Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Q1 beat and guidance lift — COO reported a Q1 EPS beat and management raised FY26 EPS and free?cash?flow guidance, citing robust momentum in MyDay and MiSight and margin expansion. This is the main fundamental positive supporting longer?term upside. Read More.
• Positive Sentiment: Bullish analyst activity — Multiple firms increased targets/ratings today (Barclays raised its target to $103 and Needham to $101; William Blair maintained a Buy), signaling continued conviction from several sell?side analysts. This creates potential catalyst if buyers follow through. Read More.
• Neutral Sentiment: Favorable growth profile highlighted by screens — Recent writeups (Zacks, other screens) point to above?average financial growth and attractive style scores, which may keep the stock on growth?oriented portfolios but don’t guarantee near?term momentum. Read More.
• Neutral Sentiment: Product/clinical news supports long run thesis — CooperVision research and product initiatives were highlighted at NCC 2026, reinforcing the durability of the contact?lens franchise. That’s positive strategically but not an immediate catalyst. Read More.
• Negative Sentiment: Market punished the stock despite the beat — Several outlets noted shares fell after the report because revenue was roughly in?line or slightly short of some street models and investors flagged regional headwinds and sluggish core vision trends. That helped drive the intraday selloff. Read More.
• Negative Sentiment: Mixed analyst/street positioning — Citigroup trimmed its target to $87 and issued Neutral, and Morgan Stanley stayed on Hold, reflecting differing views on near?term recovery in core vision that can limit upside until clearer top?line improvement is visible. Read More.

About Cooper Companies

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.